Oncology Medical News about irinotecan;recurrent glioblastoma;bevacizumab

Become a Member Today!
Register

Most Viewed Abstracts

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Friedman HS et al. – Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma

Methods

The efficacy of bevacizumab, alone and in combination with irinotecan, was determined in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial
167 patients were randomly assigned to receive bevacizumab (10 mg/kg) alone or in combination with irinotecan (340 mg/m2 or 125 mg/m2), with or without concomitant enzyme-inducing antiepileptic drugs, respectively, once every 2 weeks

Results

In the bevacizumab-alone and the bevacizumab-plus-irinotecan groups, estimated 6-month PFS rates were 42.6% and 50.3%, respectively
ORR were 28.2% and 37.8%, respectively
Median OS times were 9.2 months and 8.7 months, respectively
There was a trend for patients who were taking corticosteroids at baseline to take stable or decreasing doses over time
Of the patients treated with bevacizumab alone or bevacizumab plus irinotecan, 46.4% and 65.8%, respectively, experienced grade 3 adverse events, the most common of which were hypertension (8.3%) and convulsion (6.0%) in the bevacizumab-alone group and convulsion (13.9%), neutropenia (8.9%), and fatigue (8.9%) in the bevacizumab-plus-irinotecan group
Intracranial hemorrhage was noted in two patients (2.4%) in the bevacizumab-alone group (grade 1) and in three patients (3.8%) patients in the bevacizumab-plus-irinotecan group (grades 1, 2, and 4, respectively)